Table 2.
Response and overall survival by polymorphisms
| Marker | N | RECIST response (%) | Overall survival | ||
| Yes | No | Median (95% CI), months | Pa | ||
| COX-2 | |||||
| G/C | 12 | 0 (0) | 12 (100) | 5.9 (3.0–9.9) | 0.57 |
| G/G | 29 | 4 (14) | 25 (86) | 4.7 (3.0–8.7) | |
| Cyclin D1 | |||||
| A/A | 13 | 1 (8) | 12 (92) | 3.8 (3.0–9.9) | 0.46 |
| A/G | 18 | 1 (6) | 17 (94) | 4.9 (3.3–7.4) | |
| G/G | 10 | 2 (20) | 8 (80) | 4.5 (1.1–13.5) | |
| EGF | |||||
| A/A | 10 | 0 (0) | 10 (100) | 4.9 (3.3–7.4) | 0.92 |
| A/G | 22 | 3 (14) | 19 (86) | 3.4 (2.5–9.9) | |
| G/G | 9 | 1 (11) | 8 (89) | 7.6 (3.0–9.9) | |
| EGFR | |||||
| A/A | 21 | 2 (10) | 19 (90) | 3.3 (2.5–7.6) | 0.38 |
| A/G | 13 | 2 (15) | 11 (85) | 6.1 (4.7–10.4) | |
| G/G | 7 | 0 (0) | 7 (100) | 7.4 (1.3–13.5) | |
| EGFR (CA)n repeats | |||||
| At least 1 allele ≥20 | 17 | 0 (0) | 17 (100) | 4.7 (2.2–9.9) | 0.94 |
| Both alleles <20 | 20 | 3 (15) | 17 (85) | 4.9 (3.3–7.4) | |
| HER2 | |||||
| Ile/Ile | 28 | 3 (11) | 25 (89) | 4.8 (3.0–9.2) | 0.86 |
| Ile/Val | 10 | 1 (10) | 9 (90) | 4.7 (2.2–9.9) | |
| Val/Val | 3 | 0 (0) | 3 (100) | 5.0 (NA) | |
| IL-8 | |||||
| A/A | 14 | 4 (29) | 10 (71) | 9.6 (3.0–11.2) | 0.20 |
| A/T | 18 | 0 (0) | 18 (100) | 4.9 (3.2–7.4) | |
| T/T | 9 | 0 (0) | 9 (100) | 3.0 (2.5–4.8) | |
| TF A-603G | |||||
| A/A | 14 | 2 (14) | 12 (86) | 4.2 (3.0–9.9) | 0.37 |
| A/G | 18 | 2 (11) | 16 (89) | 5.3 (3.0–10.5) | |
| G/G | 9 | 0 (0) | 9 (100) | 6.1 (2.1–9.2) | |
| VEGF | |||||
| C/C | 30 | 1 (3) | 29 (97) | 4.9 (3.3–7.6) | 0.79 |
| C/T | 9 | 2 (22) | 7 (78) | 3.0 (3.0–10.4) | |
| T/T | 1 | 1 (100) | 0 (0) | NA | |
a
P values from Cox regression test for heterogeneity across subgroups; not adjusted for multiple comparisons.
CI, confidence interval; COX-2, cyclooxygenase-2; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IL-8, interleukin 8; N/A, not applicable; VEGF, vascular endothelial growth factor.